The Claim

In non-obese adults with type 2 diabetes and visceral adiposity, 12 weeks of daily ipragliflozin 50 mg is associated with a significant reduction in visceral fat area from baseline levels of ≥100 cm², along with improvements in HbA1c, insulin resistance, and lipid profile.

Source: Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
26score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In non-obese adults with type 2 diabetes and excess abdominal fat, taking ipragliflozin 50 mg daily for 12 weeks is associated with a measurable decrease in abdominal fat and improvements in blood sugar, insulin sensitivity, and blood fats.

See the scientific wording

In non-obese adults with type 2 diabetes and visceral adiposity, 12 weeks of ipragliflozin 50 mg daily is associated with a significant reduction in visceral fat area from ≥100 cm², alongside improvements in HbA1c, insulin resistance, and lipid profile, suggesting a broader metabolic impact beyond glycemic control.

Why this might work

By blocking sugar reabsorption in the kidneys, the body loses glucose through urine, which lowers blood sugar and insulin levels. With less insulin, fat cells stop storing fat and start breaking it down for energy. This shifts the body’s fuel source from sugar to fat, especially in deep abdominal and organ-surrounding fat deposits, leading to less visceral fat and better blood sugar and cholesterol levels.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

    In people with type 2 diabetes who aren’t overweight but have too much fat around their organs, taking ipragliflozin for 12 weeks helped shrink fat around the heart and belly, lowered blood sugar, and improved cholesterol — showing it does more than just control sugar.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.